Corporate Headquarter

SHANDONG WEIGAO BLOOD PURIFICATION PRODUCTS CO., LTD.

International Business Headquarter

WEGO HEALTHCARE (SHENZHEN) CO., LTD.

19F, Building 3, Sunmax Technology Plaza, No.8 Keyuan Road,
Nanshan District, Shenzhen, China
Tel: +86 755 33892500 Fax:+86 755 33892508
E-mail: info@wego-healthcare.com
www.wego-healthcare.com/en

The brochure copyright belongs to WEGO and all rights reserved.

Edited in Jul. 2025.



A reliable choice for **HIGH-QUALITY treatment**

WEGO


THE BLOOD PURIFICATION EXPERT

Product Feature

1 Haemodiafiltration reduces mortality risk of CKD patients

According to the Dialysis Outcomes and Practice Patterns Study (DOPPS), when compared to hemodialysis treatment, haemodiafiltration can significantly reduce patient mortality risk, with 14% reduction in all-cause mortality and 23% reduction in cardiovascular disease-related mortality.*


*Canaud B, Bragg-Gresham JL et al. Kidney Int 2006; 69:2087-2093.Sanne A.E. Peters, et al. Nephrol Dial Transplant 2016;31:978-984.



2 WEGO 3rd generation nano-spinning technology


WEGO 3rd generation membrane nano-spinning technology makes the membrane pores smoother and effectively reduces the resistance of transmembrane movement of middle and large molecules.

This innovative technology enables higher porosity on the inner surface of the membrane and increases the contact surface for substances exchange,facilitating better HDF therapy.




3 Optimized hollow fiber membrane design


- Increased hollow fiber inner diameter.
- More stable TMP performance during high-volume HDF treatment.
- Effectively reducing the frequency of TMP alarm and lowering the risk of coagulation during treatment.



4 Superior endotoxin retention capacity and biocompatibility




HDF series has superior biocompatibility while minimal effects on leukocyte level when contacts blood.




The inner compact layer of polysulfone membrane can effectively retain endotoxins to ensure patient treatment safety.

5 Better middle and large molecule endotoxin removal capacity

A randomized, parallel positive-controlled, non-inferiority trial including 216 subjects who were randomly divided into test group (HDF series) and control group in a 1:1 ratio was carried out to evaluate the efficacy and safety of the test product.





Performance Data

WEGO HAEMODIAFILTOR	HDF15	HDF16	HDF18	HDF20	HDF22	HDF23
Clearance (Qb=300ml/min, Qf=0)						
Urea	269	272	280	288	295	296
Creatinine	260	265	272	275	278	279
Phosphate	253	257	263	266	267	268
Vitamin B_{12}	166	170	177	180	185	189
Clearance (Qb=300ml/min, Qf=75ml/min)						
Urea	284	285	290	294	296	297
Creatinine	270	273	274	278	280	281
Phosphate	265	266	267	267	269	271
Vitamin B_{12}	214	218	227	233	238	240
Clearance (Qb=400ml/min, Qf=100ml/min)						
Urea	358	361	365	368	369	370
Creatinine	338	343	354	359	361	362
Phosphate	322	327	338	349	356	362
Vitamin B_{12}	253	257	266	272	276	279
UF coeff. (ml/h·mmHg)	78	83	91	95	97	98
Effective surface（m^2）	1.5	1.6	1.8	2.0	2.2	2.3
Priming volume（ml）	92	96	105	118	131	133
KoA (urea)	1123	1190	1415	1771	2402	2566
Sieving coefficient						
β2-microglobulin		0.8			0.85	
Inulin			0.95			
Albumin			≤0.003			
Max. TMP (mmHg)			500			
Inner diameter/wall thickness（μm）			220/40			
Sterilization method			γ ray			
Membrane			Polysulfone			
Housing material			Polycarbonate			
Units per box			24pcs/carton			

* Test condition:
Clearance in vitro: Qd=500ml/min, T=37°C
UF coefficient: Bovine plasma, protein content: 60±5g/L, Qb=300ml/min, TMP=50mmHg
KoA: Qb=300ml/min, Qd=500ml/min
Sieving coefficient: Qb=300ml/min, Qf=60ml/min